The fluorohydroxyapatite (FHA) FRIOS Algipore is a suitable biomaterial for the reconstruction of severely atrophic human maxillae.
Grafting of the maxillary sinus is an established treatment modality to provide sufficient bone for the fixation of dental implants. We stated the hypothesis that the porous fluorohydroxyapatitic (FHA) biomaterial FRIOS Algipore could be used as a suitable biomaterial for sinus grafting in severely atrophic maxillae. To investigate the accuracy of our hypothesis, 69 trephine specimens from 26 patients who received maxillary sinus grafting with FRIOS Algipore were retrieved during the installation of dental implants. The specimens were processed undecalcified and subjected to histomorphological and histomorphometrical examination. After a mean healing time of 7 months, 23.0% (+/-8.3) new bone had formed around the implanted particles. Bone formation was also evident within the pores of the particles. Statistical analysis indicated that bone formation originated from the sinus floor. Particles provided scaffolding for the promotion of newly formed bone towards apical sinus portions. Mineral dissolution from the walls of the pores was observed prior to and during bone apposition. Thereafter, portions of the particles were resorbed during bone remodeling and replaced by newly formed bone. The present investigation shows that the biomaterial FRIOS Algipore is a suitable biomaterial for sinus grafting of severely atrophic maxillae.
Schopper
Christian
C
University Hospital of Cranio-Maxillofacial and Oral Surgery, Medical School, University of Vienna, Vienna, Austria. mkg-forschung@akh-wien.ac.at
Moser
Doris
D
Sabbas
Alexis
A
Lagogiannis
Georgios
G
Spassova
Else
E
König
Franz
F
Donath
Karl
K
Ewers
Rolf
R
D000328:Adult; D000368:Aged; D016301:Alveolar Bone Loss / Q000473:pathology* / Q000601:surgery; D000540:Alveolar Ridge Augmentation / Q000379:methods*; D001284:Atrophy; D001672:Biocompatible Materials; D001861:Bone Regeneration; D018786:Bone Substitutes / Q000627:therapeutic use*; D003758:Dental Implantation, Endosseous / Q000379:methods; D005260:Female; D006801:Humans; D006882:Hydroxyapatites / Q000627:therapeutic use*; D008297:Male; D008437:Maxilla / Q000473:pathology* / Q000601:surgery; D008439:Maxillary Diseases / Q000473:pathology / Q000601:surgery; D008443:Maxillary Sinus / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D016348:Osseointegration; D019651:Plastic Surgery Procedures / Q000379:methods*
D001672:Biocompatible Materials; D018786:Bone Substitutes; D006882:Hydroxyapatites; C116586:fluorohydroxyapatite